Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2008 Aug;126(8):1152-6.
doi: 10.1001/archopht.126.8.1152.

Toxoplasmosis-associated neovascular lesions treated successfully with ranibizumab and antiparasitic therapy

Joseph D Benevento  1 , Rama D Jager, A Gwendolyn Noble, Paul Latkany, William F Mieler, Mari Sautter, Sanford Meyers, Marilyn Mets, Michael A Grassi, Peter Rabiah, Kenneth Boyer, Charles Swisher, Rima McLeod; Toxoplasmosis Study Group
Collaborators, Affiliations
Case Reports

Toxoplasmosis-associated neovascular lesions treated successfully with ranibizumab and antiparasitic therapy

Joseph D Benevento et al. Arch Ophthalmol. 2008 Aug.
No abstract available

PubMed Disclaimer

Conflict of interest statement

There is no conflict of interest for any of the authors involved in this study. Dr. William Mieler is on the Scientific Advisory Board of Genentech, Inc. The remaining authors do not have any commercial or proprietary interest in the ranibizumab or Genentech, Inc nor do they have any financial interests or receive payment as a consultant, reviewer, or evaluator.

Figures

Figure 1
Figure 1. Patient 1 fundus photograph, FA, and OCT
at first presentation, one month after first ranibizumab injection, two months after first ranibizumab injection, and five months after first ranibizumab injection.
Figure 2
Figure 2. Patient 2 fundus photograph, FA, and OCT
at first presentation, seven weeks after first ranibizumab injection, and eleven weeks after first ranibizumab injection.
Figure 3
Figure 3. Fundus photographs of Patients 3, 4, 5, and 6
Patient 3 (top) before CNVM and (bottom) four years after photodynamic therapy. Patient 4 (top) with CNVM and (bottom) three months later. Patient 5 (top) with CNVM and (bottom) four years later. Patient 6 (top) before and (bottom) after development of angiomatous proliferation.
See this image and copyright information in PMC

References

    1. Fine SL, Owens SL, Haller JA, Knox DL, Patz A. Choroidal neovascularization as a late complication of ocular toxoplasmosis. Am J Ophthalmol. 1981 Mar;91(3):318–322. - PubMed
    1. Cotliar AM, Friedman AH. Subretinal neovascularisation in ocular toxoplasmosis. Br J Ophthalmol. 1982 Aug;66(8):524–529. - PMC - PubMed
    1. Kayazawa F. Subretinal neovascularization associated with presumed toxoplasmic retinochoroidal scar. Ann Ophthalmol. 1982 Sep;14(9):819–821. - PubMed
    1. Uemura A, Thomas MA. Visual outcome after surgical removal of choroidal neovascularization in pediatric patients. Arch Ophthalmol. 2000 Oct;118(10):1373–1378. - PubMed
    1. Adan A, Mateo C, Wolley-Dod C. Surgery for subfoveal choroidal neovascularization in toxoplasmic retinochoroiditis. Am J Ophthalmol. 2003 Mar;135(3):386–387. - PubMed

Publication types

MeSH terms